Anti-reabsorption Medication

Presently, anti-reabsorption medication are most widely used for treating osteoporosis. Zoledronic acid (Aclasta) is a common clinical anti-reabsorption medication. As the third generation of bisphosphonates (BPs), it outperforms the previous nitrogen-containing BPs in improving patients’ balance and quality of life by inhibiting bone resorption and increasing bone mineral density (BMD). It is administered via intravenous drip infusion once a year, which, therefore, brings good compliance with treatment. However, those who have been treated with zoledronic acid intravenously are likely to suffer from acute side effects, such as fever, bone and joint pain and flulike symptoms, especially after the first administration. Although the common adverse reactions generally disappear within 72 h, or in rare cases, last 7 to 10 days without recurrence, they have serious impacts on the aging population, especially those with underlying diseases. Thus, the patients who are afraid of any adverse reactions or have suffered from any side effects during the first administration may show poor compliance with the second dose and refuse the clinical application of zoledronic acid.